March 20, 2017 08:08 AM EDT
R&D

Ae­vi shares smashed by a tri­al fail­ure for AD­HD ge­net­ic sub­group

Arsalan Arif

Founder

Ae­vi Ge­nom­ic Med­i­cine had all its eggs in one pot. And this morn­ing, that pot got smashed by a land­slide of bad da­ta. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

No­vo Nordisk’s Ca­griSe­ma shows 15.7% weight loss in sec­ond piv­otal tri­al

Beam shares promis­ing first clin­i­cal da­ta on gene edit­ing treat­ment for a lung and liv­er dis­ease 

How blue­bird's buy­out of­fer went from $100M up­front to $29M

Sun Phar­ma to ac­quire Check­point Ther­a­peu­tics and its an­ti-PD-L1 an­ti­body

Ex­clu­sive: Dai­ichi Sankyo, John­son & John­son part­ner with RNA de­liv­ery start­up No­sis Bio

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times